[Differential diagnosis between leiomyomata uteri and adenomyosis using CA 125 as a new tumor marker of ovarian carcinoma]
Other
OA: closed
CC0
⤵ 7 in-corpus citations
AI-generated summary
Serum CA 125 levels were significantly higher in women with adenomyosis (93.3 U/ml) than in those with leiomyomata uteri (18.3 U/ml), differentiating these conditions preoperatively.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
To differentiate pre-operatively between leiomyomata uteri and adenomyosis, we measured serum levels of an antigen (CA 125) common to most nonmucinous epithelial ovarian carcinoma in patients with benign uterine tumor (11 of leiomyomata uteri, 7 of adenomyosis and 1 of adenomyosis with leiomyomata uteri). CA 125 in serum samples pre and postoperatively were measured using an RIA Kit. The normal range of CA 125 levels was below 35U/ml. The mean CA 125 level (+/- S.D.) was 18.3 +/- 6.1U/ml in patients with leiomyomata uteri and 93.3 +/- 49.4U/ml in those with adenomyosis. Student's t-test showed a significant correlation (0.001 less than p less than 0.01). The mean CA 125 level in patients with adenomyosis was statistically higher than that in disease-free women. Among 7 patients with surgically demonstrable adenomyosis, the CA 125 values were over 35U/ml (87.5%). In all 11 patients with surgically demonstrable leiomyomata uteri, the CA 125 level was below 35U/ml. The CA 125 level in patients with adenomyosis gradually decreased postoperatively and in all was below 35U/ml up to one month postoperatively. Using this approach, leiomyomata uteri and adenomyosis can be differentiated, pre-operatively.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (7)
- Uterine Embolization as a New Treatment Option in Adenomyosis Uteri 2022
- Endometriosis - Recent Advances, New Perspectives and Treatments 2021
- The Incidence and Clinical Significance of Adenomyosis 2015
- CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics 2014
- Adenomyosis 2003
- Pathophysiology of adenomyosis 1998
- Clinical usefulness and false-positive results of CA 125 as a tumor marker of ovarian cancer--a study on 674 patients 1986
Source provenance
- europepmc
- last seen: 2026-10-18T09:30:06.152893+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:43:36.154433+00:00
License: CC0
· commercial use OK